{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T10:54:08Z","timestamp":1795085648661,"version":"4.10.2"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"15","license":[{"start":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T00:00:00Z","timestamp":1681430400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4,14]]},"abstract":"<jats:p>\n                    Atezolizumab is now the standard treatment for extensive-stage small cell lung cancer (ES-SCLC). Herein, we investigated the prognostic role of inflammatory markers in patients treated with atezolizumab plus chemotherapy and evaluated the efficacy and safety of adding atezolizumab to chemotherapy for patients with ES-SCLC and prognostic and predictive factors as a real-life experience. This retrospective study included 55 patients who received front-line atezolizumab with etoposide plus platin regimen for ES-SCLC. We analyzed the survival outcomes and factors that may predict response and survival. The objective response rate (ORR) was 81.8%. At a median follow-up of 23.5 months, the median progression-free survival (PFS) time was 10.8 months, and the median overall survival (OS) time was 15.2 months. In univariate analysis for PFS, limited-stage disease at the time of diagnosis, the presence of prophylactic cranial irradiation (PCI), the presence of liver metastasis, neutrophil-lymphocyte ratio (NLR), and platelet-lymphocyte ratio (PLR) were found to be prognostic factors (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = .041,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = .034,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = .031,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = .004, and\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = &lt;.001, respectively). In other words, while the median PFS time was 14.1 months in patients with PLR \u2264 135.7, it was 7.5 months in patients with &gt; 135.7. Similarly, median PFS was 14.9 months in patients with NLR \u2264 3.43, while it was 9.6 months in patients with &gt; 3.43. Univariate analysis for OS revealed that limited stage at the time of diagnosis, NLR and PLR were significant prognostic indicators (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = .01,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = .006, and\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = .007, respectively). Median OS time for patients with both NLR \u2264 3.43 and PLR \u2264 135.7 was significantly better than that of patients with NLR &gt; 3.43 and PLR &gt; 135.7 (16.9 vs 11.3 and 16.9 vs 11.5 months, respectively). Logistic regression analysis demonstrated that PLR was an independent significant predictive factor for the response to atezolizumab plus chemotherapy (OR: 0.07,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = .028). The patients with PLR \u2264 135.7 were significantly good responders to atezolizumab plus chemotherapy treatment. Real-life data demonstrated a significant correlation between survival and NLR and, PLR in ES-SCLC patients treated with atezolizumab. In addition, PLR was a significant predictive indicator of response to atezolizumab plus chemotherapy.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000033432","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T10:02:37Z","timestamp":1681466557000},"page":"e33432","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":17,"title":["Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2184-634X","authenticated-orcid":false,"given":"Yasin","family":"Kutlu","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Medipol University Faculty of Medicine, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabin Goktas","family":"Aydin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Medipol University Faculty of Medicine, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Bilici","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Medipol University Faculty of Medicine, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bala Basak","family":"Oven","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Yeditepe University Faculty of Medicine, Istanbul, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer Fatih","family":"Olmez","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Medipol University Faculty of Medicine, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozgur","family":"Acikgoz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Medipol University Faculty of Medicine, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamshid","family":"Hamdard","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Medipol University Faculty of Medicine, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1002\/ijc.27339","article-title":"Cigarette smoking and lung cancer--relative risk estimates for the major histological types from a pooled analysis of case-control studies.","volume":"131","author":"Pesch","year":"2012","journal-title":"Int J Cancer"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13045-019-0736-3","article-title":"Emerging therapies for small cell lung cancer.","volume":"12","author":"Yang","year":"2019","journal-title":"J Hematol Oncol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1634\/theoncologist.2015-0523","article-title":"The future of immunotherapy in the treatment of small cell lung cancer.","volume":"21","author":"Horn","year":"2016","journal-title":"Oncologist"},{"key":"R4-20250504","first-page":"CD001990","article-title":"Chemotherapy versus best supportive care for extensive small cell lung cancer.","author":"Agra","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1200\/JCO.2002.12.111","article-title":"Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years\u2019 follow-up.","volume":"20","author":"Sundstr\u00f8m","year":"2002","journal-title":"J Clin Oncol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer.","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1245\/s10434-015-4869-5","article-title":"Prognostic significance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in oncologic outcomes of esophageal cancer: a systematic review and meta-analysis.","volume":"23","author":"Yodying","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.hbpd.2019.03.011","article-title":"Platelet-to-lymphocyte ratio and CA19-9 are simple and informative prognostic factors in patients with resected pancreatic cancer.","volume":"18","author":"Negoi","year":"2019","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"45","DOI":"10.21037\/tlcr.2020.01.17","article-title":"Neutrophil or platelet-to-lymphocyte ratios in blood are associated with poor prognosis of pulmonary large cell neuroendocrine carcinoma.","volume":"9","author":"Shi","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.7314\/APJCP.2014.15.6.2651","article-title":"Elevated serum neutrophil to lymphocyte and platelet to lymphocyte ratios could be useful in lung cancer diagnosis.","volume":"15","author":"Kemal","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1007\/s00262-020-02637-1","article-title":"Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab.","volume":"69","author":"Simonaggio","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.lungcan.2017.07.024","article-title":"Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.","volume":"111","author":"Diem","year":"2017","journal-title":"Lung Cancer"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1097\/CM9.0000000000000536","article-title":"First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China.","volume":"132","author":"Li","year":"2019","journal-title":"Chin Med J (Engl)"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1007\/s00262-021-02926-3","article-title":"Assessment of systematic inflammatory and nutritional indexes in extensive-stage small-cell lung cancer treated with first-line chemotherapy and atezolizumab.","volume":"70","author":"Qi","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"37200","DOI":"10.18632\/oncotarget.16553","article-title":"Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?","volume":"8","author":"Deng","year":"2017","journal-title":"Oncotarget"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033432","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T22:40:17Z","timestamp":1746312017000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,14]]},"references-count":17,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000033432","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,14]]}}}